KEYSIGHT TECHNOLOGIES UK LIMITED
Company number 03809903 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: KEYSIGHT TECHNOLOGIES UK LIMITED
Company No. 03809903 | Wokingham, Berkshire | Incorporated 20 July 1999
1. Financial Health Score: A− (Provisional)
This company presents as a structurally robust patient with no visible symptoms of distress. The grade is provisional rather than a full "A" for one reason: the dataset provided contains no filed financial figures (no balance sheet, P&L, or cash flow data), so the deeper "bloodwork" — profitability, liquidity, and solvency ratios — could not be tested. The grade therefore reflects excellent vital signs on every observable indicator, discounted slightly for the absence of granular financial verification.
2. Key Vital Signs
| Vital Sign | Reading | Interpretation |
|---|---|---|
| Pulse (Status) | Active | Strong, steady heartbeat. No insolvency, administration, or liquidation flags. |
| Blood Pressure (Filing Compliance) | Accounts to 31 Oct 2025 filed; confirmation statement to 4 Jul 2026; nothing overdue | Regular check-ups attended on time. Late filings are often the first symptom of distress — none here. |
| Age & Longevity | 26 years trading | A mature patient that has survived multiple economic cycles (dot-com bust, 2008, pandemic). |
| Transparency (Accounts Category) | Full accounts filed | Voluntarily comprehensive disclosure — the equivalent of a patient who shares their full medical history rather than hiding symptoms. |
| Family Support (Ownership) | Keysight Technologies Inc owns >75% of shares and voting rights, with right to appoint/remove directors | Wholly controlled by a major US-listed multinational parent. This is a powerful financial immune system — the subsidiary is unlikely to be allowed to fail in isolation. |
| Governance (Officers) | Two directors and a secretary, all current; no disqualification records | Clean bill of conduct. No history of the "lifestyle diseases" of corporate life (director misconduct, disqualification). |
| Genetic History (Previous Names) | Hewlett-Packard Measurement UK → Agilent Technologies UK → Keysight Technologies UK | Name changes track well-documented corporate spin-offs (HP → Agilent 1999, Agilent → Keysight 2014), not distress rebranding. This is healthy corporate evolution, not a patient changing identity to escape creditors. |
One notable reading — Share Capital of £1.00: To an untrained eye this looks alarming, but for a wholly-owned subsidiary it is entirely normal. Capital is typically provided by the parent through intercompany funding rather than share capital. It does, however, mean the company has minimal standalone financial cushioning — its health is umbilically linked to its parent.
3. Symptoms Analysis
No distress symptoms detected. The screening shows: - ✅ No overdue filings (often the earliest fever of financial trouble) - ✅ No insolvency events, liquidation, or administration markers - ✅ No director disqualifications - ✅ Long, continuous trading history under blue-chip ownership
Minor observations (not clinically significant): - The PSC register lists Keysight Technologies Inc twice with slightly different name formats — a cosmetic administrative duplication, not a concern. - The SIC code (82990 – Other business support services) suggests this entity likely operates as an intra-group service company rather than a standalone trading business. Such entities commonly run on stable cost-plus arrangements with the parent, which typically means predictable, low-volatility financial performance.
The missing test results: Without the actual figures, I cannot assess net current assets (working capital), the P&L reserve trend, or any intercompany debt burden. These matter, and the recommendation below addresses obtaining them.
4. Diagnosis
Overall condition: Healthy, well-supported corporate subsidiary with no indicators of financial distress.
The clinical picture is of a patient in good shape who also has a very wealthy family guaranteeing their medical bills. Every observable marker — compliance discipline, governance cleanliness, longevity, transparent reporting, and 100% backing from a substantial US technology group — points to financial wellness. The principal structural caveat is dependency: with £1 share capital, this entity's financial health is essentially a reflection of Keysight Technologies Inc's willingness and ability to support it. The parent's covenant strength is, in practice, this company's covenant strength.
Prognosis: Stable to Positive
Barring an unlikely shock at the parent level, the outlook is favourable. The 25-year unbroken trading record, clean compliance history, and full-accounts transparency suggest continuity. The main forward risk is group restructuring (as evidenced by the HP → Agilent → Keysight lineage, this entity's role can change with corporate strategy), but historically such changes here have been orderly evolutions, not distress events.
5. Recommendations
- Order the full bloodwork. Obtain the filed accounts for the year to 31 October 2025 from Companies House and review: net current assets, P&L reserve trajectory, turnover, and any intercompany balances. This converts the provisional A− into a definitive grade.
- For creditors and counterparties: seek parental cover. Given the nominal £1 share capital, anyone extending significant credit should request a parent company guarantee or letter of comfort from Keysight Technologies Inc — insure against the dependency risk identified above.
- Assess the parent, not just the patient. Any material commercial reliance on this entity should include a review of Keysight Technologies Inc's own financial health (it is US-listed, so filings are publicly available).
- Monitor filing timeliness as an early-warning system. The next accounts are due 31 July 2027 and the next confirmation statement 18 July 2027. Any future lateness would be the first symptom worth investigating.
- Clarify the trading relationship. If entering a contract, confirm whether this entity contracts on its own account or as a group service vehicle, and verify which group entity ultimately bears performance obligations.